

Amendments to the Claims

This listing of the claims will replace all prior versions and listings of the claims.

Listing of Claims:

- 1-15. (canceled)
16. (previously presented) An isolated polynucleotide comprising a nucleic acid encoding amino acids 2 to 127 of SEQ ID NO:2.
17. (previously presented) The isolated polynucleotide of claim 16, comprising nucleotide 15 to 392 of SEQ ID NO:1.
18. (previously presented) The isolated polynucleotide of claim 16, comprising a nucleic acid encoding amino acids 1 to 127 of SEQ ID NO:2.
19. (previously presented) The isolated polynucleotide of claim 18, comprising nucleotide 12 to 392 of SEQ ID NO:1.
20. (previously presented) The isolated polynucleotide of claim 16, which is DNA.
21. (previously presented) The isolated polynucleotide of claim 16, which is RNA.
22. (previously presented) The isolated polynucleotide of claim 16, further comprising a heterologous polynucleotide.
23. (previously presented) The isolated polynucleotide of claim 22, wherein said heterologous polynucleotide encodes a heterologous polypeptide.
24. (previously presented) A method of producing a vector that comprises inserting the isolated polynucleotide of claim 16 into a vector.

25. (previously presented) A vector comprising the isolated polynucleotide of claim 16.

26. (previously presented) The vector of claim 25, wherein said polynucleotide is operably associated with a heterologous regulatory sequence.

27. (previously presented) A host cell comprising the isolated polynucleotide of claim 16.

28. (previously presented) The host cell of claim 27, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

29. (previously presented) A method of producing a polypeptide that comprises culturing the host cell of claim 28 under conditions such that said polypeptide is expressed, and recovering said polypeptide.

30. (previously presented) A composition comprising the isolated polynucleotide of claim 16 and a pharmaceutically acceptable carrier.

31. (previously presented) An isolated polynucleotide comprising a nucleic acid encoding the completed amino acid sequence encoded by the cDNA clone of ATCC Deposit No. 97856.

32. (previously presented) The isolated polynucleotide of claim 31, which is DNA.

33. (previously presented) The isolated polynucleotide of claim 31, which is RNA.

34. (previously presented) The isolated polynucleotide of claim 31, further comprising a heterologous polynucleotide.

35. (previously presented) The isolated polynucleotide of claim 34, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

36. (previously presented) A method of producing a vector that comprises inserting the isolated polynucleotide of claim 31 into a vector.

37. (previously presented) A vector comprising the isolated polynucleotide of claim 31.

38. (previously presented) The vector of claim 37, wherein said polynucleotide is operably associated with a heterologous regulatory sequence.

39. (previously presented) A host cell comprising the isolated polynucleotide of claim 31.

40. (previously presented) The host cell of claim 39, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

41. (previously presented) A method of producing a polypeptide that comprises culturing the host cell of claim 40 under conditions such that said polypeptide is expressed, and recovering said polypeptide.

42. (previously presented) A composition comprising the isolated polypeptide of claim 31 and a pharmaceutically acceptable carrier.

43. (canceled)

44. (previously presented) An isolated polynucleotide fragment of SEQ ID NO:1 consisting of at least 100 contiguous nucleotides of the coding region of SEQ ID NO:1 or the complement thereof.

45. (previously presented) The isolated polynucleotide fragment of claim 44, consisting of at least 250 contiguous nucleotides of the coding region of SEQ ID NO:1 or the complement thereof.

46. (previously presented) The isolated polynucleotide of claim 44, which is DNA.

47. (previously presented) The isolated polynucleotide of claim 44, which is RNA.

48-49. (canceled)

50. (previously presented) A method of producing a vector that comprises inserting the isolated polynucleotide of claim 44 into a vector.

51. (previously presented) A vector comprising the isolated polynucleotide of claim 44.

52. (canceled)

53. (previously presented) A host cell comprising the isolated polynucleotide of claim 44.

54-56. (canceled)

57. (previously presented) An isolated polynucleotide, encoding a fragment of SEQ ID NO:2 selected from the group consisting of:

(a) a polypeptide consisting of at least amino acids 94 to 107 of SEQ ID NO:2; and

(b) a polypeptide consisting of at least amino acids 120 to 127 of SEQ ID NO:2.

58. (previously presented) The isolated polynucleotide of claim 57, wherein said polypeptide is (a).

59. (previously presented) The isolated polynucleotide of claim 57, wherein said polypeptide is (b).

60. (previously presented) The isolated polynucleotide of claim 57, which is DNA.

61. (previously presented) The isolated polynucleotide of claim 57, which is RNA.

62. (previously presented) The isolated polynucleotide of claim 57, further comprising a heterologous polynucleotide.

63. (previously presented) The isolated polynucleotide of claim 62, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

64. (previously presented) A method of producing a vector that comprises inserting the isolated polynucleotide of claim 57 into a vector.

65. (previously presented) A vector comprising the isolated polynucleotide of claim 57.

66. (previously presented) The vector of claim 65, wherein said polynucleotide is operably associated with a heterologous regulatory sequence.

67. (previously presented) A host cell comprising the isolated polynucleotide of claim 57.

68. (previously presented) The host cell of claim 67, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

69. (previously presented) A method of producing a polypeptide that comprises culturing the host cell of claim 68 under conditions such that said polypeptide is expressed, and recovering said polypeptide.

70. (previously presented) A composition comprising the isolated polynucleotide of claim 57 and a pharmaceutically acceptable carrier.

71-79. (canceled)